Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Sky One Starts Shift From OTC To Prescription Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Sky One Medical entered 11 new drugs enter into clinical trials, seven of which are injectable drugs, the company announced June 10, which could lead to the company's first foray into the injectable drug market in China
Advertisement

Related Content

A Very Good Time For Acquisitions – China Sky One Sees Opportunities In Financial Crisis
A Very Good Time For Acquisitions – China Sky One Sees Opportunities In Financial Crisis
China Sky One Moves to NASDAQ To Raise Brand Awareness
China Sky One Moves to NASDAQ To Raise Brand Awareness
China Sky One Reports 140 Percent Increase In Revenue, Lists on American Stock Exchange
China Sky One Reports 140 Percent Increase In Revenue, Lists on American Stock Exchange
Advertisement
UsernamePublicRestriction

Register

SC069056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel